Celyad Oncology Reports 2022 Financial Results and Recent Highlights – 03/23/2023 at 22:01
Mont-Saint-Guibert, Belgium – Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor T-cell (CAR-T) therapies , today announces its financial results for the year 2022 as of December 31, 2022 and presents an update of its activities.
Michel Lussier, Interim CEO of Celyad Oncology, comments: “2022 was a pivotal year for Celyad Oncology, with important changes and turning points. We are convinced that all these changes, together with our previous achievements, have significantly strengthened our position. Having met the challenges of 2022, Celyad has positively reinvented itself as a leaner and more agile organization. We believe Celyad is well prepared and has the unique strengths and know-how to create significant value for its shareholders over the coming years.”